Safety Evaluation and Risk Management of Omeprazole

ZHANG Ting,LIANG Wei,LIU Fang
2012-01-01
Abstract:OBJECTIVE: To evaluate the safety of omeprazole,probe into the regular pattern and characteristics of its adverse reaction(ADR) and incompatibility and give advice on its risk management.METHODS: We compared the package inserts of omeprazole in China and abroad,retrieved the pertinent literature from CNKI(1991-2011) regarding the ADR and incompatibility of omeprazole and for which a meta-analysis was performed.RESULTS: There were significant differences among the package inserts of omeprazole in different dosage forms from different manufactures,especially in the indications,drug use for specific populations and ADR report.A total of 103 papers of ADR reports of omeprazole in China were included,with the ADR of blood system(presented predominantly as reduction of white blood cell count) showing the highest proportion,accounting for 26.97%(48/178),followed by allergic reaction of 19.66%(35/178);66 papers regarding the omeprazole-related incompatibility in China were included,which reported that omeprazole was incompatible with vitamin C and some other medicines and which occurred mostly during the continuous drip infusion and the omeprazole should better be dissolved in 100 ml 0.9% sodium.CONCLUSION: Omeprazole is a widely used proton pump inhibitor and its adverse reaction is clear and mild with spontaneous remission in most cases.The risk management of omeprazole can be achieved by tightening control on indications,paying attention to drug use for special population,tightening monitoring on serious adverse reactions and standardizing the intravenous administration in an attempt to achieve safe medication.
What problem does this paper attempt to address?